Effect of colchicine on progression of known coronary atherosclerosis in patients with STable CoROnary artery disease CoMpared to placebo (EKSTROM) trial—rationale and design
Study context
- Population
- Patients with stable CAD and known coronary atherosclerosisplanned enrolment
- Participants
- 84 patients
- Planned comparison
- Colchicine 0.5mg/day vs placebo
- Primary endpoint
- Change in low attenuation plaque volume measured by coronary CT angiography (CCTA)
- Follow-up
- 12 months
Methodological detailsdouble-blind, placebo-controlled, 1:1 randomisation, add-on to standard of care, coronary computed tomography angiography (CCTA) at baseline and 12 months, 100% enrolled as of November 2023; expected end of study by Q2 2024
- Double-blind
- Placebo-controlled
- 1:1 randomisation
- Add-on to standard of care
- CCTA at baseline and 12 months
- 100% enrolled as of November 2023; expected end of study by Q2 2024
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Effect of colchicine on progression of known coronary atherosclerosis in patients with STable CoROnary artery disease CoMpared to placebo (EKSTROM) trial—rationale and design. Am Heart J. Published 17 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →